|
|
Article: Testing drug-protein affinities.(Life Science)(Measuring Enzyme-Substrate Affinities)(Caldera Pharmaceuticals)(Brief Article)
- Article from:
- R & D
- Article date:
- September 1, 2005
CopyrightCOPYRIGHT 2005 Advantage Business Media. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Measuring the binding affinity between a drug candidate and human proteins is a key element in the development of new drugs. A number of options exist for screening drugs against a few proteins, but few methods exist for screening a drug against many proteins. A system developed by George Havrilla at Los Alamos National Laboratory, N.M., and Benjamin Warner at Caldera Pharmaceuticals, also in Los Alamos, named MESA (Measuring Enzyme-Substrate Affinities), corrects this technology gap by rapidly and inexpensively measuring the full pharmacological profile--both therapeutic and toxicological--of drugs, thus allowing ...
Related newspaper, magazine, and journal articles:
|
|
Article: Researchers at University of Regensburg release new data on ...
Blood Weekly;
May 14, 2009 ;
700+ words
... ... States of America report (see also Protein Scaffolds). "The best evolved variants show turnover numbers and substrate affinities that are similar to those of wild-type enzymes catalyzing the same reaction. The determination of the crystal ...
|
|